Professor Shabir Madhi Earns Prestigious Global Vaccine Award

The National Foundation for Infectious Diseases (NFID), a leading public health organisation in the United States, announced that Madhi will receive the 2026 Maxwell Finland Award for Scientific Achievement.

South African vaccinologist and public health expert Professor Shabir A. Madhi has been selected to receive one of the world's most respected honours in infectious disease research, recognising a career that has transformed vaccine science and improved health outcomes for millions of people.

The National Foundation for Infectious Diseases (NFID), a leading public health organisation in the United States, announced that Madhi will receive the 2026 Maxwell Finland Award for Scientific Achievement. The award is presented to scientists whose work has made significant and lasting contributions to the prevention and control of infectious diseases.

Madhi, who is based at the University of the Witwatersrand (Wits University) in Johannesburg, has become one of Africa's most influential voices in vaccinology. His research has shaped immunisation policies across the world and strengthened efforts to combat some of the most serious infectious diseases affecting children and vulnerable populations.

Research Influenced Global Vaccination Programmes

Among Madhi's most notable achievements is his leadership of a landmark South African study involving nearly 40,000 children that demonstrated the effectiveness of pneumococcal conjugate vaccines. The findings played an important role in supporting the approval of improved vaccines and deepening scientific understanding of pneumonia, one of the leading causes of child deaths worldwide.

The widespread adoption of pneumococcal vaccines is now credited with preventing hundreds of thousands of child deaths globally. Madhi also made major contributions to rotavirus vaccine research, helping provide evidence that informed international recommendations for vaccine use in low- and middle-income countries where severe diarrhoeal diseases continue to threaten young children.

His work has extended well beyond childhood immunisation. Widely recognised as a pioneer in maternal vaccination, Madhi led the world's first randomised controlled trial of influenza vaccination during pregnancy. The study demonstrated that vaccination could protect both pregnant women and their infants, opening new possibilities for disease prevention before birth.

He has also led groundbreaking research into maternal vaccines against respiratory syncytial virus (RSV) and Group B Streptococcus, both of which can cause serious illness in newborns and infants.

Global Impact Reached Beyond the COVID-19 Pandemic

Madhi's leadership gained international attention during the COVID-19 pandemic when he directed Africa's first SARS-CoV-2 vaccine trials. The research generated crucial evidence that informed vaccine strategies and public health decisions during a period of global uncertainty.

Announcing the award, Washington Research Foundation President and Chief Executive Officer Orin S. Levine praised Madhi's influence on global health and vaccine policy. He described the South African scientist's career as an example of rigorous scientific research, visionary leadership and lasting impact on disease prevention. Beyond his research achievements, Madhi has invested heavily in developing future scientific leaders across Africa. Through mentorship and training programmes, he has helped build a new generation of vaccinologists, infectious disease experts and public health researchers, strengthening the continent's capacity for medical research and innovation.

Madhi will formally receive the Maxwell Finland Award at the NFID Awards Gala in Washington, DC, on 20 October 2026. The ceremony will also honour other global health leaders for their contributions to pandemic preparedness, vaccine development and public health leadership.